Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AVID100 |
Synonyms | |
Therapy Description |
AVID100 is an antibody-drug conjugate (ADC) comprising an EGFR-targeted antibody linked to a cytotoxic drug, which potentially results in decreased growth of EGFR-expressing tumors (Eur J Cancer, Dec 2016, Vol 69, S147). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AVID100 | AVID-100|AVID 100 | EGFR Antibody 60 | AVID100 is an antibody-drug conjugate (ADC) comprising an EGFR-targeted antibody linked to a cytotoxic drug, which potentially results in decreased growth of EGFR-expressing tumors (Eur J Cancer, Dec 2016, Vol 69, S147). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03094169 | Phase I | AVID100 | AVID100 in Advanced Epithelial Carcinomas | Terminated | USA | 0 |